BioDelivery Sciences International (BDSI) Stock Price, News & Analysis

Company Overview

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.

Key Stats

• Today's Range: $5.59 to $5.60
• 50-Day Range: $5.54 to $5.60
• 52-Week Range: $2.50 to $5.62
• Volume: 2.09 million shs
• Average Volume: 3.34 million shs
• Market Capitalization: $577.05 million
• P/E Ratio: 6.74
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BDSI Stock Analysis - Frequently Asked Questions

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced its quarterly earnings data on Tuesday, November, 2nd. The specialty pharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.01. The specialty pharmaceutical company had revenue of $41.09 million for the quarter, compared to analysts' expectations of $42.05 million. BioDelivery Sciences International had a trailing twelve-month return on equity of 21.25% and a net margin of 50.90%.

What other stocks do shareholders of BioDelivery Sciences International own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioDelivery Sciences International investors own include NVIDIA (NVDA), Bristol Myers Squibb (BMY), TG Therapeutics (TGTX), Meta Platforms (META), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 11/02/2021
• Today: 7/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:BDSI
• CIK: 1103021
• Web: www.bdsi.com
• Phone: (919) 582-9050
• Fax: 919-582-9051
• Employees: 200
• Year Founded: 1997

Profitability

• EPS (Trailing Twelve Months): $0.83
• Trailing P/E Ratio: 6.74
• Forward P/E Ratio: 14.71
• P/E Growth: N/A
• Net Income: $84.86 million
• Net Margins: 50.90%
• Pretax Margin: 17.77%
• Return on Equity: 21.25%
• Return on Assets: 10.56%

Debt

• Debt-to-Equity Ratio: 0.29
• Current Ratio: 2.45
• Quick Ratio: 2.17

Sales & Book Value

• Annual Sales: $166.70 million
• Price / Sales: 3.46
• Cash Flow: $0.36 per share
• Price / Cash Flow: 15.42
• Book Value: $1.90 per share
• Price / Book: 2.94

Miscellaneous

• Outstanding Shares: 103,229,000
• Free Float: 92,927,000
• Market Cap: $577.05 million
• Optionable: Optionable
• Beta: 0.56